Fewer, Bigger, Bolder: IPO Proceeds Up 155% in 2026 as Biotech Reopens the Window
bIAnk AI Research · August 2026 · 7 min
US IPO count is down 23% year-to-date but proceeds are up 155% to roughly $28.3bn, and early August brought a flurry of biotech listings. The equity window is open — but only for scale, and only for issuers that can price against a public comparable rather than a private mark.
Renaissance Capital data through early August 2026 shows 102 US IPOs of $50m or more priced year-to-date, a 23.3% decline in count versus the same point in 2025 — yet aggregate proceeds of approximately $28.3bn, up 155.1%. That divergence is the entire story of this cycle: the market is not broadly open, it is open at size.
The first week of August delivered a cluster of biotech pricings, the clearest signal since 2021 that risk appetite has returned to clinical-stage equity. Biotech is the canary because it is the purest duration trade in public markets: investors buying pre-revenue assets are implicitly saying they are comfortable with the discount rate.
Behind the listings sits a private market that still needs liquidity. PitchBook's Q2 2026 US PE Breakdown and its midyear outlook describe subdued exit and fundraising conditions, with sponsors holding assets longer than underwritten. Every reopened IPO window is therefore doing double duty — pricing new capital and clearing an exit backlog that continuation vehicles alone cannot absorb.
On the credit side the picture is repair rather than distress. LPs committed $234.1bn across more than 200 private debt funds in the most recent cycle, and PitchBook's June 2026 US Private Credit Monitor frames the asset class as "bruised, not broken" after the software-sector stress that prompted Jamie Dimon's "cockroach" warning. Spreads have widened but the bid for paper has not disappeared.
What this means for issuers preparing 2026-2027 processes: the dual-track is back, and it is genuinely dual. A credible IPO alternative is currently worth 0.5-1.0x EBITDA of negotiating leverage in a sale process, because trade and sponsor buyers know the seller has a real second option. But the bar to be IPO-credible has risen — two years of audited accounts under the target listing standard, a public-comparable narrative, and float economics that work above roughly $300m of proceeds.
For mid-market companies below that threshold, the read is different and important: the public window is not your window. The efficient path remains a structured private raise or a controlled sale, priced off the same improved sentiment that is lifting IPO valuations without incurring listing cost and disclosure drag.
Key takeaways
- US IPOs ≥$50m: 102 priced YTD 2026 (-23.3% in count) but ~$28.3bn raised (+155.1% y/y)
- A cluster of biotech pricings in early August marks the clearest risk-appetite signal since 2021
- Private credit framed as "bruised, not broken": $234.1bn committed across 200+ private debt funds
- A credible IPO alternative is currently worth 0.5-1.0x EBITDA of leverage in a parallel sale process